370 related articles for article (PubMed ID: 12238926)
1. Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.
Gao ZG; Kim SK; Biadatti T; Chen W; Lee K; Barak D; Kim SG; Johnson CR; Jacobson KA
J Med Chem; 2002 Sep; 45(20):4471-84. PubMed ID: 12238926
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of efficacy at A3 adenosine receptors: modification of the ribose moiety.
Gao ZG; Jeong LS; Moon HR; Kim HO; Choi WJ; Shin DH; Elhalem E; Comin MJ; Melman N; Mamedova L; Gross AS; Rodriguez JB; Jacobson KA
Biochem Pharmacol; 2004 Mar; 67(5):893-901. PubMed ID: 15104242
[TBL] [Abstract][Full Text] [Related]
3. (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
Tchilibon S; Joshi BV; Kim SK; Duong HT; Gao ZG; Jacobson KA
J Med Chem; 2005 Mar; 48(6):1745-58. PubMed ID: 15771421
[TBL] [Abstract][Full Text] [Related]
4. Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.
Melman A; Wang B; Joshi BV; Gao ZG; Castro Sd; Heller CL; Kim SK; Jeong LS; Jacobson KA
Bioorg Med Chem; 2008 Sep; 16(18):8546-56. PubMed ID: 18752961
[TBL] [Abstract][Full Text] [Related]
5. Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications.
Lee K; Ravi G; Ji XD; Marquez VE; Jacobson KA
Bioorg Med Chem Lett; 2001 May; 11(10):1333-7. PubMed ID: 11392549
[TBL] [Abstract][Full Text] [Related]
6. Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor.
Kim SK; Gao ZG; Jeong LS; Jacobson KA
J Mol Graph Model; 2006 Dec; 25(4):562-77. PubMed ID: 16793299
[TBL] [Abstract][Full Text] [Related]
7. Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.
Jacobson KA; Ji X; Li AH; Melman N; Siddiqui MA; Shin KJ; Marquez VE; Ravi RG
J Med Chem; 2000 Jun; 43(11):2196-203. PubMed ID: 10841798
[TBL] [Abstract][Full Text] [Related]
8. Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
Siddiqi SM; Jacobson KA; Esker JL; Olah ME; Ji XD; Melman N; Tiwari KN; Secrist JA; Schneller SW; Cristalli G
J Med Chem; 1995 Mar; 38(7):1174-88. PubMed ID: 7707320
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.
Li AH; Moro S; Forsyth N; Melman N; Ji XD; Jacobson KA
J Med Chem; 1999 Feb; 42(4):706-21. PubMed ID: 10052977
[TBL] [Abstract][Full Text] [Related]
10. Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides.
Jacobson KA; Gao ZG; Chen A; Barak D; Kim SA; Lee K; Link A; Rompaey PV; van Calenbergh S; Liang BT
J Med Chem; 2001 Nov; 44(24):4125-36. PubMed ID: 11708915
[TBL] [Abstract][Full Text] [Related]
11. 5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors.
van Tilburg EW; van der Klein PA; von Frijtag Drabbe Künzel J; de Groote M; Stannek C; Lorenzen A; IJzerman AP
J Med Chem; 2001 Aug; 44(18):2966-75. PubMed ID: 11520205
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.
Jacobson KA; Siddiqi SM; Olah ME; Ji XD; Melman N; Bellamkonda K; Meshulam Y; Stiles GL; Kim HO
J Med Chem; 1995 May; 38(10):1720-35. PubMed ID: 7752196
[TBL] [Abstract][Full Text] [Related]
13. Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.
Gao ZG; Joshi BV; Klutz AM; Kim SK; Lee HW; Kim HO; Jeong LS; Jacobson KA
Bioorg Med Chem Lett; 2006 Feb; 16(3):596-601. PubMed ID: 16289820
[TBL] [Abstract][Full Text] [Related]
14. Partial agonists for A(3) adenosine receptors.
Gao ZG; Jacobson KA
Curr Top Med Chem; 2004; 4(8):855-62. PubMed ID: 15078216
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
Cappellacci L; Franchetti P; Pasqualini M; Petrelli R; Vita P; Lavecchia A; Novellino E; Costa B; Martini C; Klotz KN; Grifantini M
J Med Chem; 2005 Mar; 48(5):1550-62. PubMed ID: 15743197
[TBL] [Abstract][Full Text] [Related]
16. N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors.
Gao ZG; Blaustein JB; Gross AS; Melman N; Jacobson KA
Biochem Pharmacol; 2003 May; 65(10):1675-84. PubMed ID: 12754103
[TBL] [Abstract][Full Text] [Related]
17. N6,5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor.
van Tilburg EW; von Frijtag Drabbe Künzel J; de Groote M; Vollinga RC; Lorenzen A; IJzerman AP
J Med Chem; 1999 Apr; 42(8):1393-400. PubMed ID: 10212125
[TBL] [Abstract][Full Text] [Related]
18. Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists.
Kim SK; Gao ZG; Van Rompaey P; Gross AS; Chen A; Van Calenbergh S; Jacobson KA
J Med Chem; 2003 Nov; 46(23):4847-59. PubMed ID: 14584936
[TBL] [Abstract][Full Text] [Related]
19. Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives.
Gao ZG; Kim SG; Soltysiak KA; Melman N; IJzerman AP; Jacobson KA
Mol Pharmacol; 2002 Jul; 62(1):81-9. PubMed ID: 12065758
[TBL] [Abstract][Full Text] [Related]
20. Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor.
Gao ZG; Chen A; Barak D; Kim SK; Müller CE; Jacobson KA
J Biol Chem; 2002 May; 277(21):19056-63. PubMed ID: 11891221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
